This is a rare type of cancer that starts in the T cells, a type of white blood cell. It's caused by a virus called HTLV-1. It mainly affects adults and is more common in certain parts of the world like Japan and the Caribbean. It can affect the blood, lymph nodes, and other organs.
Every report comes from a Lived member, sent anonymously.
Have you had Chemotherapy infusion for ATLL?
Adult T-cell leukemia-lymphoma (ATLL) is a rare cancer of T cells, a type of white blood cell that helps direct the immune system. It develops in a small number of people who have carried a virus called human T-lymphotropic virus type 1 (HTLV-1) for many years. The abnormal T cells can build up in the blood (the leukemia part of the name), in lymph nodes and other organs (the lymphoma part), and often in the skin. ATLL behaves very differently from one person to the next, so doctors sort it into four types. The acute and lymphoma types are aggressive: they grow quickly and commonly cause swollen lymph nodes, an enlarged liver or spleen, skin lesions and a high level of calcium in the blood. The chronic and smoldering types grow more slowly and may show up only as abnormal blood counts or a long-lasting rash, but about half eventually change into the acute type. In every type, the disease weakens the immune system, which makes unusual infections more likely.
HTLV-1 infection is the cause of ATLL. The virus passes from mother to child mainly through breastfeeding, and it can also spread through sex and through infected blood products. It is most common in southwestern Japan, the Caribbean, parts of Central and South America and sub-Saharan Africa, and some areas of the Middle East and Australia. Cases in North America and Europe occur mostly among people with family ties to those regions. Carrying HTLV-1 does not mean someone will develop cancer. Most carriers stay healthy for life; an estimated 2.5% to 5% develop ATLL, usually decades after infection, and nearly all of them were infected in early childhood. The average age at diagnosis is in the early 60s, and men and women are affected about equally. Among carriers, a higher amount of virus in the blood and smoking have been linked to greater risk, though these findings come mostly from a small number of studies in Japan. HTLV-1 can also cause other problems, including a slowly progressive disease of the spinal cord.
Diagnosis combines a test for the virus with tests that show the cancer cells themselves. A blood test for HTLV-1 antibodies shows whether someone carries the virus; on its own, a positive result does not mean cancer. A blood count and a blood smear look for abnormal T cells, which in ATLL often have a lobed, petal-like nucleus sometimes called a flower cell. Flow cytometry, a lab test that identifies cells by the markers on their surface, confirms what kind of T cells they are. When there is no tumor to sample, ATLL is generally diagnosed when at least 5% of the lymphocytes circulating in the blood are these abnormal cells. If the disease appears in a lymph node or the skin, a biopsy of that tissue is examined. Further tests establish the type, which guides treatment. These include blood calcium and lactate dehydrogenase (LDH, an enzyme that is often raised in the aggressive types), imaging such as a CT or PET-CT scan, and sometimes a bone marrow sample. Because ATLL skin lesions can look like eczema, psoriasis or another skin lymphoma called mycosis fungoides, experts advise HTLV-1 testing for anyone diagnosed with a T-cell lymphoma, particularly people from regions where the virus is common.
Treatment depends mainly on the type. For smoldering ATLL that causes no symptoms, the usual approach is active monitoring: regular visits and blood tests, with treatment started if the disease changes. Monitoring is also an option for chronic ATLL with favorable features. Skin lesions can be treated directly with steroid creams, light therapy or radiation. Outside Japan, a combination of zidovudine (an antiviral also used for HIV, often called AZT) and interferon alfa (a drug that acts on immune signaling) is used when chronic or smoldering ATLL needs treatment, and it tends to work best in the types that involve the blood. The acute and lymphoma types need prompt treatment. Options include combination chemotherapy, usually a standard lymphoma regimen called CHOP in the United States and Europe, and for the acute type, zidovudine with interferon alfa where it is available. Because aggressive ATLL spreads to the brain or spinal cord in about 10% to 20% of people, chemotherapy given into the spinal fluid is often added as prevention. Responses to chemotherapy alone usually do not last, so experts recommend early referral to a transplant center for people well enough to consider an allogeneic stem cell transplant. This replaces the bone marrow with cells from a donor, whose immune cells can then attack the cancer. A transplant offers the best chance of long-term control, and large studies report long-term survival in roughly a third of recipients, but it carries serious risks, including graft-versus-host disease, in which donor immune cells attack the recipient's own tissues. Newer drugs are used mainly when the disease returns or does not respond. Mogamulizumab is an antibody that targets a protein called CCR4 on ATLL cells. It is approved for ATLL in Japan and available in the United States, where it is approved for other T-cell lymphomas but not specifically for ATLL. It is usually avoided in the weeks before a transplant because it raises the risk of severe graft-versus-host disease. Lenalidomide, valemetostat and, for cancers carrying a marker called CD30, brentuximab vedotin have each produced responses in some people. For older adults or people who cannot have a transplant, gentler chemotherapy followed by maintenance treatment is a reasonable option. Because most evidence in ATLL comes from small studies, experts recommend considering a clinical trial for everyone with the disease.
The outlook depends heavily on the type. The acute and lymphoma types remain difficult to treat, with a median survival of less than a year in many studies, although some people reach long remissions, particularly after a transplant. Treatment for these types is intensive and often involves hospital stays, repeated infusions and, after a transplant, months of close follow-up. The chronic and smoldering types can remain stable for years, and many people keep up their usual routines with periodic checkups. Even so, published series report median survival of roughly 3 to 5 years for these types, and progression to the acute type is common, so regular blood tests and skin checks matter even when someone feels well. The immune weakness in ATLL comes from the disease itself, not only from treatment. Infections that rarely affect healthy people are common, even in the slower-growing types, including a lung infection caused by the fungus Pneumocystis, a parasitic gut infection called strongyloidiasis and fungal meningitis. Care teams watch for these closely throughout the course of the illness.
If you carry HTLV-1 or come from a region where it is common, arrange a medical evaluation for a rash or skin lumps that do not go away, swollen lymph nodes, soaking night sweats, or unexplained weight loss or tiredness. If you are being monitored for chronic or smoldering ATLL, tell your care team promptly about new or growing skin lumps, enlarging lymph nodes or fevers, since these can signal a change to a more aggressive type. Call your care team right away for a fever of 100.5°F (38°C) or higher, chills or other signs of infection, since infections in ATLL and during its treatment can become serious quickly. Also call right away for extreme thirst, urinating much more often, nausea or vomiting, constipation, muscle weakness or new confusion, which can mean a high blood calcium level.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with ATLL is like, what's helped you, or ask the community a question.